BMYBRISTOL MYERS SQUIBB CO
Pharmaceutical Preparations
- Revenue
- $48.2B
- 0.2% YoY
- Operating margin
- —
- EBITDA
- —
- Market cap
- $127.7B
- Employees
- 32,500
- $1M revenue each
- Net debt / EBITDA
- —
- $33.0B net debt
- AI in 10-K
- 1.4
- mentions per 10K words
Takeover score 0 of 13
Fixable underperformance 0 of 7
- TSR below peersNo—3+ of last 5 years
- High CEO pay despite TSRNo—Median CEO pay ≥ $15M while TSR trails
- Earnings not backed by cashNo201% of net incomeCash flow under 80% of net income
- Dilutive SBCNo1% of revenueOver 10% of revenue
- Payouts exceed cash flowNo36% of cash flowBuybacks + dividends over cash flow
- Goodwill-heavyNo24% of assetsOver 40% of assets
- Shareholder dissentNo95% lowest supportAny vote under 80% support
Buyer economics 0 of 4
- Low revenue per employeeNo$1M · 84th pctBottom quartile of its SIC industry
- Quiet on AINo1.4 per 10K words · 44th pctBottom quartile of AI mentions in 10-Ks
- Net cashNo—More cash than debt, positive EBITDA
- Buyout-sizedNo$127.7B market capMarket cap $500M–$5B
Catalysts 0 of 2
- Active 13DNo0 filingsActive-intent 13D in 18 months
- Net insider sellingNo−$2M netNet sales over $10M in 12 months
Financials
| Metric | FY2021 | FY2022 | FY2023 | FY2024 | FY2025 | YoY |
|---|---|---|---|---|---|---|
| Revenue | $46.4B | $46.2B | $45.0B | $48.3B | $48.2B | 0.2% |
| Net income | $7.0B | $6.3B | $8.0B | −$8.9B | $7.1B | 179% |
| Operating cash flow | $16.2B | $13.1B | $13.9B | $15.2B | $14.2B | 6.8% |
| Capex | $973M | $1.1B | $1.2B | $1.2B | $1.3B | 5.0% |
| Stock-based comp | $583M | $457M | $518M | $507M | $553M | 9.1% |
| Buybacks | $6.3B | $8.0B | $5.2B | $0 | $0 | |
| Dividends | $4.4B | $4.6B | $4.7B | $4.9B | $5.0B | 3.7% |
Deal filings
None.
13D filers
None on file.
Insider trading
- Open-market buys, 12 mo
- $0 · 0
- Open-market sells, 12 mo
- $2M · 4
- Net
- −$2M
Pay vs performance
No pay-versus-performance disclosure yet.